Yangi Klivlend klinikasi tadqiqotlari birinchi marta limfoma va leykemiya uchun FDA tomonidan tasdiqlangan ibrutinib (ibrutinib) eng keng tarqalgan va o'limga olib keladigan miya o'smalarini davolashda yordam berishi va bir kun kelib glioblastomali bemorlarda qo'llanilishi va omon qolish darajasini yaxshilashi mumkinligini ko'rsatadi.
Amerika miya shishi assotsiatsiyasining hisobotiga ko'ra, glioblastomaning omon qolish darajasi juda past va standart davolanishni olgan bemorlarning o'rtacha omon qolish muddati 15 oydan kam. Glioblastoma eng halokatli asosiy miya shishi bo'lib, hozirgi davolash usullariga juda chidamli. Ushbu bemorlarni imkon qadar tezroq yangi davolash usullari bilan ta'minlash zarurati mavjud.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain o'smalari in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
